Please check your internet connection and try again.
## Atorvastatin
### Overview
Atorvastatin is a statin medication that inhibits HMG-CoA reductase, an enzyme involved in cholesterol synthesis. It lowers total cholesterol, LDL cholesterol, and triglycerides, and can increase HDL cholesterol.
### Primary Indications
* Hyperlipidemia (mixed dyslipidemia, hypercholesterolemia)
* Prevention of cardiovascular events in patients with risk factors for coronary heart disease.
### Adult Dosing
* **Hyperlipidemia:** Initial dose is typically 10-20 mg once daily. Titrate to achieve lipid goals. Maintenance doses range from 10-80 mg once daily.
* **Cardiovascular Risk Reduction:** 10-80 mg once daily.
Maximum dose: 80 mg once daily.
### Pediatric Dosing
* **Ages 10-17 years with heterozygous familial hypercholesterolemia:** 10 mg once daily. Doses can be increased to 20 mg once daily. (Max 40 mg daily in this age group).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Patients with active liver disease or unexplained persistent elevations of liver transaminases should not use atorvastatin. Consider dose reduction in patients with a history of liver disease.
* **Renal Impairment:** No dose adjustment is typically needed.
### Contraindications
* Active liver disease or unexplained persistent elevations of serum transaminases.
* Hypersensitivity to atorvastatin or any component of the formulation.
* Pregnancy and breastfeeding.
### Adverse Effects
* **Common:** Myalgia, arthralgia, diarrhea, nausea, headache, nasopharyngitis.
* **Serious:** Rhabdomyolysis with acute kidney injury, hepatotoxicity, increased blood glucose levels, memory impairment.
### Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., itraconazole, ketoconazole, clarithromycin, protease inhibitors):** Increased risk of myopathy and rhabdomyolysis. Use with caution or consider alternative therapies.
* **Gemfibrozil and other fibrates:** Increased risk of myopathy. Concurrent use is generally not recommended.
* **Niacin:** Increased risk of myopathy.
* **Colchicine:** Increased risk of myopathy and rhabdomyolysis.
* **Grapefruit Juice:** May increase atorvastatin plasma concentrations; limit intake.
### Monitoring
* **Baseline:** Liver function tests (ALT, AST) and creatine kinase (CK).
* **During Therapy:** Lipid panel at baseline and typically within 4-12 weeks of initiating or changing dose, then periodically as clinically indicated. Monitor for signs and symptoms of myopathy (muscle pain, tenderness, weakness) and liver dysfunction (jaundice, dark urine, abdominal pain).
### Clinical Pearls
* Administer at any time of day, with or without food.
* Counsel patients on the importance of reporting muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.
* Consider concomitant therapy for patients with very high LDL-C levels or those who do not achieve adequate response with maximal statin therapy.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for clinical judgment. Always consult the most current prescribing information, professional guidelines, and local protocols before making any treatment decisions.
